Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

CAR-T therapies in Haematological Malignancy: Update Bulletin #3 [January 2019]

Product Code:
596201270
Publication Date:
January 2019
Format:
PDF
Price:
$1,315

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US on a variety of recent events in the CAR-T therapy space. KOLs provide their candid insights on key data that were presented at the 60th American Society of Hematology Annual Meeting (ASH 2018), including:  Initial data from the Phase I CRB-402 trial of Bluebird Bio and Celgene’s anti-BCMA CAR-T cell therapy bb21217 in multiple myeloma; long-term data from the pivotal ELIANA and JULIET studies of the anti-CD19 CAR-T therapy Kymriah (tisagenlecleucel; Novartis) in children and young adults with relapsed or refractory acute lymphoblastic leukaemia (ALL), and adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), respectively; results from a small-scale study suggesting a potential augmentation of efficacy for CD19-directed CAR T-cell therapy when given in combination with a PD-1 inhibitor.

Business Questions:

• How do KOLs interpret the preliminary data released from the Phase I CRB-402 trial of Bluebird Bio and Celgene’s anti-BCMA CAR-T cell therapy bb21217?
• In terms of efficacy and tolerability, how does bb21217 compare with its predecessor bb2121?
• What is future outlook for bb21217 in a treatment for multiple myeloma?
• How do KOLs view the long-term, follow-up data released from the pivotal ELIANA and JULIET studies of Novartis’ anti-CD19 CAR-T therapy Kymriah?
• How are the ELIANA and JULIET trial data interpreted in terms of durability of response, safety and tolerability?
• How do KOLs view the potential for PD-1 inhibition to salvage responses to CAR-T therapy in paediatric patients with ALL?
• Is there a convincing rationale for combining PD-1 inhibition with anti-CD19 CAR-T therapy and does this have risks in terms of safety?
• How do KOLs view the potential for PD-1 inhibition combined with anti-CD19 CAR-T therapy to play a role in the future treatment algorithm for ALL?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved